IL2RA and non-Hodgkin lymphoma: Camidanlumab tesirine has been tested in CD25-expressing hematological malignancies including CD25+ AML (NCT02588092, 34 patients in total) (54), relapsed/refractory (R/R) Hodgkin lymphoma (NCT04052997) and non-Hodgkin lymphoma (NCT02432235).